Replimune REPL stock
Ionis Tryngolza Wins FDA Approval, Expands to 3.6 Million Patients
Ionis Pharmaceuticals submitted a label expansion and the FDA said yes. Replimune has now been rejected twice on the same melanoma drug and just got the FDA to accept a third attempt, this time with an advisory committee meeting attached. One company is celebrating a smooth approval. The other is celebrating an agency that will…
